OncoMatch/Clinical Trials/NCT06390956
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Is NCT06390956 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pirtobrutinib and Rituximab for marginal zone lymphoma.
Treatment: Pirtobrutinib · Rituximab — The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: antibiotic therapy — for H. pylori, C. psittaci, and B. burgdorferi
Prior antibiotic therapy for H. pylori, C. psittaci, and B. burgdorferi
Must have received: antiviral therapy — for HCV
Prior antiviral therapy for HCV
Lab requirements
Blood counts
ANC ≥ 750 cells/mm3 (≥ 0.75 x 10^9/L) independent of G-CSF support (≥500 if bone marrow involvement or splenomegaly); Platelet count ≥ 50,000/mm3 (≥30,000 if bone marrow involvement); Hemoglobin ≥ 8 g/dL (≥7 g/dL if bone marrow involvement or splenomegaly)
Kidney function
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
Liver function
Total Bilirubin ≤ 1.5x ULN (≤3x ULN if liver involvement); AST(SGOT)/ALT(SGPT) ≤ 3 × ULN (≤5x ULN if liver metastases)
Cardiac function
QTcF ≤ 470 ms; LVEF ≥ 40% within 12 months prior to first dose
Adequate organ function as defined as: Hematologic: ANC ≥ 750 cells/mm3...; Platelet count ≥ 50,000/mm3...; Hemoglobin ≥ 8 g/dL...; Hepatic: Total Bilirubin ≤ 1.5x ULN...; AST(SGOT)/ALT(SGPT) ≤ 3 × ULN...; Renal: Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula; aPPT or PT or INR ≤ 1.5 X ULN; Cardiac: QTcF > 470 ms excluded, LVEF < 40% excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University · St Louis, Missouri
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06390956 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages